GUIDED THERAPEUTICS INC
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
GTHPStored price and day change unavailable
Contents
Item 1. Financial Statements Unaudited Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025
| GUIDED THERAPEUTICS, INC. AND SUBSIDIARY | ||
|---|---|---|
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||
| (unaudited, in thousands) | ||
| March 31, | December 31, | |
| 2026 | 2025 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $369 | $63 |
| Accounts receivable, net of allowance for credit losses of $4 at March 31, 2026 and December 31, 2025 | 4 | 4 |
| Inventory, net of reserves of $818 at March 31, 2026 and December 31, 2025 | 469 | 448 |
| Other current assets | 69 | 90 |
| Total current assets | 911 | 605 |
| Non-Current Assets: | ||
| Property and equipment, net | 13 | 16 |
| Operating lease right-of-use asset, net of amortization | 663 | 686 |
| Other assets | 17 | 17 |
| Total non-current assets | 693 | 719 |
| TOTAL ASSETS | $1,604 | $1,324 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current Liabilities: | ||
| Accounts payable | $2,277 | $2,416 |
| Accounts payable, related parties | 32 | 31 |
| Accrued liabilities | 1,129 | 1,170 |
| Deferred compensation conversion liability, at fair value | 331 | 548 |
| Deferred revenue | 189 | 189 |
| Current portion of lease liability | 58 | 45 |
| Current portion of long-term debt, related parties | 430 | 621 |
| Short-term notes payable | 65 | 82 |
| Short-term convertible notes, net of discounts | 264 | 347 |
| Short-term convertible debt in default | 1,150 | 1,150 |
| Derivative liability at fair value | 37 | 37 |
| Total current liabilities | 5,962 | 6,636 |
| Long-Term Liabilities | ||
| Long-term lease liability | 627 | 651 |
| Long-term notes payable | 17 | 23 |
| Long-term debt, related parties | 174 | 20 |
| Total long-term liabilities | 818 | 694 |
| Total liabilities | 6,780 | 7,330 |
| COMMITMENTS AND CONTINGENCIES (Note 6) | ||
| STOCKHOLDERS’ DEFICIT: | ||
| Series C preferred stock, $0.001 par value; 9.0 shares authorized; no shares issued or outstanding as of March 31, 2026 and December 31, 2025. | - | - |
| Series C1 convertible preferred stock, $0.001 par value; 20.3 shares authorized, 0.4 shares issued and outstanding as of March 31, 2026 and December 31, 2025. Liquidation preference of $374 at March 31, 2026 and December 31, 2025. | 61 | 61 |
| Series C2 preferred stock, $0.001 par value; 5,000 shares authorized, no shares issued or outstanding as of March 31, 2026 and December 31, 2025. | - | - |
| Series D preferred stock, $0.001 par value; 6.0 shares authorized, 0.1 shares issued and outstanding as of March 31, 2026 and December 31, 2025. Liquidation preference of $50 at March 31, 2026 and December 31, 2025. | 18 | 18 |
| Series E preferred stock, $0.001 par value; 5.0 shares authorized, 0.2 and 0.3 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. Liquidation preference of $200 and $300 at March 31, 2026 and December 31, 2025, respectively. | 189 | 284 |
| Series F preferred stock, $0.001 par value; 1.5 shares authorized, 0.3 and 1.0 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. Liquidation preference of $271 and $981 at March 31, 2026 and December 31, 2025, respectively. | 226 | 817 |
| Series F-2 preferred stock, $0.001 par value; 3.5 shares authorized, 0.2 and 0.5 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. Liquidation preference of $245 and $480 at March 31, 2026 and December 31, 2025, respectively. | 223 | 438 |
| Common stock, $0.001 par value; 500,000 shares authorized, 96,508 and 86,154 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. | 3,481 | 3,471 |
| Additional paid-in capital | 148,826 | 146,092 |
| Treasury stock at cost | (132) | (132) |
| Accumulated deficit | (158,068) | (157,055) |
| Total stockholders’ deficit | (5,176) | (6,006) |
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | $1,604 | $1,324 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.